A phase I/II study of safety and efficacy of orteronel (TAK-700), an oral, investigational, nonsteroidal 17,20-lyase inhibitor, with docetaxel and prednisone (DP) in metastatic castration-resistant prostate cancer (mCRPC): Updated phase II results.
Daniel Petrylak
Consultant or Advisory Role - Amgen; Amgen; Amgen; Bayer; Bayer; Bayer; Dendreon; Dendreon; Dendreon; Ferring; Ferring; Ferring; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Johnson & Johnson; Johnson & Johnson; Johnson & Johnson; Millennium; Millennium; Millennium (U); Novartis; Novartis; Novartis; Pfizer; Pfizer; Pfizer
Research Funding - AstraZeneca; AstraZeneca; AstraZeneca; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Celgene; Celgene; Celgene; Dendreon; Dendreon; Dendreon; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Millennium; Millennium; Pfizer; Pfizer; Pfizer; Rogosen Institute; Rogosen Institute; Sanofi ; Sanofi ; Sanofi
Jitendra G. Gandhi
No relevant relationships to disclose
William R. Clark
Research Funding - Astellas Pharma; Bristol-Myers Squibb; Lilly; Millennium; Roll Global; Watson Pharmaceuticals
Elisabeth I. Heath
Research Funding - Millennium
Jianqing Lin
No relevant relationships to disclose
William K. Oh
Consultant or Advisory Role - Astellas Pharma; Janssen Pharmaceutical ; Medivation
David B. Agus
Consultant or Advisory Role - Millennium
Bradley Curtis Carthon
No relevant relationships to disclose
Susan Moran
Employment or Leadership Position - Millennium
Ning Kong
Employment or Leadership Position - Millennium
Ajit Suri
Employment or Leadership Position - Millennium
Michael Bargfrede
Employment or Leadership Position - Millennium
Glenn Liu
No relevant relationships to disclose